Abstract
The development of multifunctional theranostic agents has become an intriguing venture for personalized oncology, because they can integrate tumor diagnosis and therapy. One approach explored to obtain such multifunctional theranostic agents is through the chemical conjugation of anticancer drugs and contrast agents with various cancer-targeted ligands. The other approach is based on the nanoplatform, in which cancer-targeted nanostructures achieve simultaneous cancer specific detection and therapeutics either by EPR effect or by conjugation of target ligands. Interestingly, a newly emerging strategy from multifunctional small molecules to develop cancertargeted theranostic agents has been reported recently. In consideration of the urgent need and rapid development of theranostic agents in cancer therapy, herein we review the currently adopted and newly emerging approaches for their preparation, and highlight the promises and challenges in each approach, hoping to offer useful insights in developing more specific and efficient cancer theranostic agents suitable for clinical use.
Keywords: Cancer theranostics, multifunctional agents, near-infrared imaging, cyanine dyes, nanotheranostic agents.
Current Medicinal Chemistry
Title:Newly Emerging Theranostic Agents for Simultaneous Cancertargeted Imaging and Therapy
Volume: 23 Issue: 5
Author(s): Shenglin Luo, Xiaochao Yang and Chunmeng Shi
Affiliation:
Keywords: Cancer theranostics, multifunctional agents, near-infrared imaging, cyanine dyes, nanotheranostic agents.
Abstract: The development of multifunctional theranostic agents has become an intriguing venture for personalized oncology, because they can integrate tumor diagnosis and therapy. One approach explored to obtain such multifunctional theranostic agents is through the chemical conjugation of anticancer drugs and contrast agents with various cancer-targeted ligands. The other approach is based on the nanoplatform, in which cancer-targeted nanostructures achieve simultaneous cancer specific detection and therapeutics either by EPR effect or by conjugation of target ligands. Interestingly, a newly emerging strategy from multifunctional small molecules to develop cancertargeted theranostic agents has been reported recently. In consideration of the urgent need and rapid development of theranostic agents in cancer therapy, herein we review the currently adopted and newly emerging approaches for their preparation, and highlight the promises and challenges in each approach, hoping to offer useful insights in developing more specific and efficient cancer theranostic agents suitable for clinical use.
Export Options
About this article
Cite this article as:
Luo Shenglin, Yang Xiaochao and Shi Chunmeng, Newly Emerging Theranostic Agents for Simultaneous Cancertargeted Imaging and Therapy, Current Medicinal Chemistry 2016; 23 (5) . https://dx.doi.org/10.2174/0929867323666151223095718
DOI https://dx.doi.org/10.2174/0929867323666151223095718 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology ATTEMPTS System: A Macromolecular Prodrug Strategy for Cancer Drug Delivery
Current Pharmaceutical Design PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Current Overview of Anti-Angiogenic Therapies for Patients with Epithelial Ovarian Cancer)
Current Angiogenesis (Discontinued) Penetration of Tamoxifen Citrate Loaded Ethosomes and Liposomes Across Human Skin: A Comparative Study with Confocal Laser Scanning Microscopy
Current Drug Delivery Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Improved Prediction of Lysine Acetylation by Support Vector Machines
Protein & Peptide Letters Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An <i>In Silico</i> Approach
Current Cancer Drug Targets Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research The Role of Antioxidant Enzymes in the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews Emerging Role of GPR30/GPER1 in Skeletal Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design